Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045784 | 1.00 | CHRM2 (0.44) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL12564459 | 1.00 | CHRM2 (0.44) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL1987752 | 1.00 | CHRM2 (0.44) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL10500589 | 0.78 | CHRM2 (0.52) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL13772148 | 0.78 | ALDH1A1 (0.53) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL4048126 | 0.78 | ALDH1A1 (0.53) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL11913658 | 0.76 | ALDH1A1 (0.52) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL12830800 | 0.76 | CHRM2 (0.59) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL13813857 | 0.74 | CHRM2 (0.49) | CHRM2CHRM4CHRM5SIGMAR1ACHE | |
| SCHEMBL1993494 | 0.73 | CHRM2 (0.47) | CHRM2CHRM4CHRM5SIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152238-A1 | PHARMACEUTICAL COMPOUNDS | OPRD1, OPRK1, OPRM1 | CHRM2 40/4885CHRM4 36/4885CHRM5 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.